OnKure Therapeutics (NASDAQ:OKUR – Free Report) – Research analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of OnKure Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($4.03) for the year, up from their prior forecast of ($4.31). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ FY2026 earnings at ($3.05) EPS and FY2027 earnings at ($3.74) EPS.
Several other brokerages have also recently weighed in on OKUR. Leerink Partners initiated coverage on OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of OnKure Therapeutics in a research note on Friday, November 8th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $36.00.
OnKure Therapeutics Stock Down 0.5 %
Shares of NASDAQ:OKUR opened at $5.82 on Monday. The company has a market capitalization of $19.44 million, a PE ratio of -0.48 and a beta of 0.25. The company’s 50-day moving average is $8.33. OnKure Therapeutics has a 12-month low of $4.57 and a 12-month high of $20.00.
OnKure Therapeutics Company Profile
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Featured Stories
- Five stocks we like better than OnKure Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What is the Hang Seng index?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Stock Splits, Do They Really Impact Investors?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
